Browsing Tag
Leqembi
11 posts
Leqembi gains traction in China as commercial insurance innovative drug list expands access for Alzheimer’s patients
Leqembi gains commercial insurance status in China, opening doors for Alzheimer’s patients and transforming access. Find out what this means for BioArctic AB and Eisai.
Can early LEQEMBI treatment delay Alzheimer’s by 8 years? Eisai reveals long-term data at CTAD 2025
Find out how Eisai and Biogen's LEQEMBI may slow Alzheimer’s by over 8 years in early-stage patients, as new CTAD 2025 data reveals long-term benefits.
Etalanetug shows over 90% tau biomarker reduction in Eisai’s DIAD trial update at CTAD 2025
Eisai’s etalanetug shows up to 90% reduction in novel tau biomarker in Alzheimer’s patients. Find out how it could reshape the AD treatment landscape.
Leqembi UK approval: BioArctic, Eisai win MHRA nod for once-monthly Alzheimer’s treatment
BioArctic’s Leqembi now approved for monthly IV use in UK Alzheimer’s patients. Find out what this means for long-term treatment worldwide.
BioArctic advances exidavnemab phase 2a cohorts after safety review
BioArctic expands its Phase 2a trial for exidavnemab after a successful safety review. Read how this impacts Parkinson’s and MSA drug development today.
FDA approves Leqembi maintenance dosing for early Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi (lecanemab-irmb), an…
FDA accepts application for LEQEMBI subcutaneous dosing: A step forward in Alzheimer’s care
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted…
Eisai initiates rolling submission for Leqembi autoinjector BLA to FDA
BioArctic AB’s partner Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S.…
Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s…
Quanterix launches diagnostic test aiding early Alzheimer’s detection
Quanterix, a biomarker detection firm powering scientific research and breakthrough diagnostics, has introduced LucentAD, a new test designed…